Pasar al contenido principal

IMPLICACION DEL REPRESOR CIC IN TUMORES DE PULMON IMPULSADOS POR KRAS Y EN LA RESISTENCIA A TERAPIAS DIRIGIDAS

PID2020-116705RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

  • Salmón, Marina
  • Álvarez-Díaz, Ruth
  • Fustero-Torre, Coral
  • Brehey, Oksana
  • Lechuga, Carmen G.
  • Sanclemente, Manuel
  • Fernández-García, Fernando
  • López-García, Alejandra
  • Martín-Guijarro, María Carmen
  • Rodríguez-Perales, Sandra
  • Bousquet-Mur, Emily
  • Morales-Cacho, Lucía
  • Mulero, Francisca
  • Al-Shahrour, Fátima
  • Martínez, Lola
  • Domínguez, Orlando
  • Caleiras, Eduardo
  • Ortega, Sagrario
  • Guerra, Carmen
  • Musteanu, Mónica
  • Drosten, Matthias
  • Barbacid, Mariano
KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy and the emergence of tumor resistance between genetic ablation of mutant Kras expression and pharmacological inhibition of oncogenic KRAS activity. Whereas Kras ablation induces massive tumor regression and prevents the appearance of resistant cells in vivo, treatment of KrasG12C/Trp53-driven lung adenocarcinomas with sotorasib, a selective KRASG12C inhibitor, caused a limited antitumor response similar to that observed in the clinic, including the rapid onset of resistance. Unlike in human tumors, we did not observe mutations in components of the RAS-signaling pathways. Instead, sotorasib-resistant tumors displayed amplification of the mutant Kras allele and activation of xenobiotic metabolism pathways, suggesting that reduction of the on-target activity of KRASG12C inhibitors is the main mechanism responsible for the onset of resistance. In sum, our results suggest that resistance to KRAS inhibitors could be prevented by achieving a more robust inhibition of KRAS signaling mimicking the results obtained upon Kras ablation., This work was supported by grants from the European Research Council (ERC-GA 695566, THERACAN); the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033) (grant RTC2017-6576-1), cofunded by ERDF “A way of making Europe”; the Autonomous Community of Madrid (B2017/BMD-3884 iLung-CM), cofunded by FSE and ERDF “A way of making Europe”; the CRIS Cancer Foundation, the Scientific Foundation of the Spanish Association Against Cancer (GC166173694BARB); an ERA PerMed grant, funded by the Instituto de Salud Carlos III (AC20/00114), the Scientific Foundation of the Spanish Association Against Cancer (PERME20707BARB) and the European Union’s Horizon 2020 program (779282) to MB; and the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant RTI2018-094664-B-I00), cofunded by ERDF “A way of making Europe” to MM and MB. Additional funding included grants from the Spanish National Research and Development Plan, Instituto de Salud Carlos III, ERDF “A way of making Europe” (PI20/01837 and DTS19/00111); the Scientific Foundation of the Spanish Association Against Cancer (LABAE20049RODR) to SRP; the Instituto de Salud Carlos III (PI19/00514), cofunded by ERDF “A way of making Europe” to CG; the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-116705RB-I00); and the Scientific Foundation of the Spanish Association Against Cancer (LABAE211678DROS) to MD. MB is a recipient of an endowed chair from the AXA Research Fund. M Salmón was supported by a predoctoral contract “Severo Ochoa” (BES-2016-079096) from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación. OB is a recipient of a fellowship from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación. FFG was supported by a Formación de Profesorado Universitario (FPU) fellowship from the Ministerio de Universidades., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HRS-4642: The next piece of the puzzle to keep KRAS in check

  • Flores-Gómez, Alejandra A.
  • Drosten, Matthias
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial., The authors would like to acknowledge funding from the Spanish Ministry of Science and Innovation (PID2020-116705RB-100) and the Asociación Española Contra el Cáncer (LABAE211678DROS). A.A.F.-G. is supported by a CONACYT fellowship from the Mexican government., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

  • Ballesteros-González, Irene
  • Hernández-Navas, Iván
  • Brehey, Oksana
  • Lechuga, Carmen G.
  • Salmón, Marina
  • Scotece, Morena
  • Velasco-Vicente, Ricardo
  • Flores-Gómez, Alejandra A.
  • Cebriá, Antonio
  • Simón-Carrasco, Lucía
  • Jiménez, Gerardo
  • Musteanu, Monica
  • Guerra, Carmen
  • Domínguez, Orlando
  • Caleiras, Eduardo
  • Blanco-Aparicio, Carmen
  • Pons, Tirso
  • Ferrer, Irene
  • Paz-Ares, Luis
  • Torres-Ruiz, Raul
  • Rodríguez-Perales, Sandra
  • Barbacid, Mariano
  • Drosten, Matthias
KRAS mutations are responsible for a quarter of all lung adenocarcinomas. However, the molecular mechanisms linking these mutations and their frequent secondary dosage amplification to tumor formation are still not fully understood. While ample evidence supports a crucial role for the MAPK pathway in tumor development, the primary effectors targeted by this pathway remain largely unexplored. Here we identify the transcriptional repressor Capicua (CIC) as a key target inactivated by KRAS/MAPK signaling in lung adenocarcinoma. We show that genetic loss of CIC recapitulates the phenotypic consequences of amplified KRAS signaling. Genetic disruption of CIC suppressed the requirement for Kras allelic imbalances and accelerated the transformation of bronchiolar Club cells. We also demonstrate that restoring CIC repressor activity impaired proliferation of CIC-deficient tumor cells and reverted resistance to MAPK pathway inhibitors. These results highlight the key role of CIC during lung tumor formation and suggest that selective pressure for effective CIC inactivation favors secondary amplification of KRAS/MAPK signaling in tumor cells., This work was supported by a grant from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-116705RB-I00) to M.D. M.D. also received funding from the Scientific Foundation of the Spanish Association Against Cancer (grant LABAE211678DROS). This work was further supported by a grant from the Scientific Foundation of the Spanish Association Against Cancer (Programa Excelencia 2022 grant EPAEC222641CICS); grants from Instituto de Salud Carlos III, co-funded by FEDER (grants PI23/01932 and PI21/01641) and the Scientific Foundation of the Spanish Association Against Cancer (grant LABAE20049RODR) to S.R.-P.; as well as a grant from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-119248GB-I00) to G.J. T.P. was supported in part by a grant from the Comunidad de Madrid (grant P2022/BMD-7321/MITIC-CM). This work was also supported in part by grants from the European Research Council (ERC-AG/695566 [THERACAN]), the Comunidad de Madrid (B2017/BMD-3884 iLUNG-CM) and the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (RTI2018-094664-B-I00) to M.B. M.B. is a recipient of an Endowed Chair from the AXA Research Fund. O.B. was a recipient of a fellowship from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (PRE2019-091685). M.Salmón was supported by a predoctoral contract “Severo Ochoa” from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (BES-2016-079096). A.A.F.-G. was a recipient of a CONAHCYT fellowship from the Mexican Government. L.S.-C. was supported by a Postdoctoral Research Contract from the Scientific Foundation of the Spanish Association Against Cancer (POSTD211274SIMÓ)., Peer reviewed